Skip to content

The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome

The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01883154
Enrollment
160
Registered
2013-06-21
Start date
2013-09-30
Completion date
2023-09-30
Last updated
2013-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal Pregnancies

Brief summary

Genetic and environmental factors are believed to play a major role in intrauterine growth and intrauterine programming. We intend to study genetic factors such as Telomere homeostasis, senescence, genomic instability and the presence of Genomic copy number variations in placental tissue from pregnancies complicated with Intrauterine growth restriction(IUGR), Gestational and pre gestational Diabetes, placentas from IVF pregnancies and from normal pregnancies. We also intend to assess these factors in cord blood and maternal blood.

Detailed description

Based on the previous data from our group as well as other laboratories, we postulate that there is a correlation between impaired telomere homeostasis, senescence genomic instability and intra-uterine programming in placentas and in fetuses exposed to suboptimal intrauterine conditions such as hypoxia or hyperglycemia. Improved understanding of the mechanisms that produce the genomic changes in IUGR placentas and their influence on later risks of developing the metabolic syndrome should provide basis for future research that might lead into improved outcome of IUGR fetuses.

Interventions

None listed

Sponsors

Meir Medical Center
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* A diagnosis of Intrauterine growth restriction * A diagnosis of Gestational diabetes * A diagnosis of pre gestational Diabetes * IVF pregnancy

Exclusion criteria

* chorioamnionitis * meconium stained amniotic fluid * A request of the patient for Cord blood retrieval for preservation

Design outcomes

Primary

MeasureTime frame
Rate of Copy Number Variations10 yeras

Secondary

MeasureTime frame
Telomere length10 years
Number of copies of mitochondrial DNA10 years

Countries

Israel

Contacts

Primary ContactTal Biron Shental, MD
Tal.Biron-Shental@clalit.org.il972-52-836-2331
Backup ContactRivka Sukenik-Halevy, MD
riki.sukenik@gmail.com972-52-6007249

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026